EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies

Wei Zhao, Mindy Engevik, Julian G. Hurdle

ACS Infectious Diseases · 13.11.2026

DOI: 10.1021/acsinfecdis.6c00683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Wei Zhao und 2 weiteren Autor:innen. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health and Human Services.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile infection (CDI) remains a leading cause of healthcare-associated diarrhea, arising largely from antimicrobial-induced displacement of the gut microbiota. Although antimicrobial therapy remains the clinical standard for CDI, high rates of recurrence, the spread of antimicrobial-resistant strains, and inadequate interventions for countering toxin-mediated tissue damage highlight the need for alternative strategies. In this review, we evaluate emerging nonantimicrobial approaches for CDI, focusing on microbial-derived metabolites (including short-chain fatty acids and bile acids), plant-derived phytochemicals, and host-directed therapeutics that modulate inflammatory and neuroimmune pathways. Mechanistic insights into how these strategies mitigate C. difficile pathogenesis are also examined, including roles in attenuating intestinal inflammation and preserving epithelial barrier function. Given the multifactorial nature of CDI, we propose there is a need to advance a new therapeutic framework that integrates narrow-spectrum antimicrobials with nonantimicrobial host-directed modalities. Collectively, this conceptual framework provides a rational foundation for developing next-generation interventions for CDI in an era characterized by multidrug resistance and aging populations with comorbidities that are risk factors for CDI.

Förderung

  • U.S. Department of Health and Human Services

Zitieren

APA

Zhao, W., Engevik, M., & Hurdle, J. G. (2026). Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6c00683

Vancouver

Zhao W, Engevik M, Hurdle JG. Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.6c00683

BibTeX
@article{Zhao2026,
  author = {Zhao, Wei and Engevik, Mindy and Hurdle, Julian G.},
  title = {Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.6c00683}
}
Kostenlos starten →